Peptide Therapeutics - Global Strategic Business Report

The global market for Peptide Therapeutics was valued at USD 43.7 Billion in 2024 and is projected to reach USD 56.3 Billion by 2030, growing at a CAGR of 4.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Peptide Therapeutics Market - Key Trends & Drivers Summarized

How Are Technological Advances Enhancing Peptide Therapeutics Development?

The development of peptide therapeutics has been greatly accelerated by technological advances, enabling the creation of more stable, potent, and targeted therapies. Peptides, which are naturally occurring biological molecules, serve as signaling agents in the body and have high specificity for their targets, making them attractive candidates for therapeutic development. Innovations in peptide engineering have led to the development of modified peptides that resist enzymatic degradation, improve bioavailability, and have extended half-lives, allowing for less frequent dosing. Furthermore, advances in delivery systems, such as nanoparticle encapsulation and peptide-drug conjugates, are improving the effectiveness of peptide-based treatments by enabling targeted delivery to specific tissues or cells. Technologies such as peptide stapling, which stabilizes the peptide structure, and the use of peptidomimetics, which mimic peptide activity while enhancing stability, are also contributing to the growth of peptide therapeutics. These innovations are enabling the development of peptides that can treat a wide range of conditions, from metabolic disorders to oncology and infectious diseases, with greater efficacy and fewer side effects.

Why Are Peptide Therapeutics Gaining Popularity in Modern Medicine?

Peptide therapeutics are gaining significant popularity in modern medicine due to their unique ability to interact with specific receptors and cellular targets, offering precision in treatment that is often unmatched by small molecules or traditional biologics. Peptides are known for their high specificity and low toxicity, which makes them particularly attractive in the treatment of chronic diseases such as cancer, cardiovascular diseases, and metabolic disorders. Peptide-based therapies, including GLP-1 agonists for diabetes and vasopressin receptor antagonists for heart failure, have shown remarkable efficacy, driving their adoption in clinical settings. Additionally, peptides are increasingly being explored for their role in immunotherapy, with peptide vaccines being developed to trigger immune responses against cancers and infectious diseases. The relatively simple and scalable manufacturing processes for peptides compared to larger biologics also make them a cost-effective option for drug development. As the demand for targeted and safer therapies grows, peptide therapeutics are becoming a key focus in the development pipelines of major pharmaceutical companies.

How Are Industry and Healthcare Trends Shaping the Peptide Therapeutics Market?

Industry and healthcare trends are playing a significant role in shaping the peptide therapeutics market, particularly with the rise of personalized medicine and targeted therapies. As the healthcare sector shifts toward individualized treatments, peptides are becoming integral due to their ability to target specific molecular pathways associated with disease progression. This is particularly true in oncology, where peptides are being used for targeted drug delivery and as agents in cancer immunotherapies. The growing prevalence of chronic diseases, especially diabetes and obesity, has also led to increased interest in peptide therapeutics, with drugs like GLP-1 analogs becoming standard treatments for these conditions. Furthermore, advancements in biotechnology are making it easier to modify peptides for improved stability, bioavailability, and delivery, which is expanding their therapeutic potential. The rise of biologics and the focus on reducing the side effects associated with conventional therapies are further accelerating the development of peptide-based drugs across multiple therapeutic areas.

What Factors Are Driving Growth in the Peptide Therapeutics Market?

The growth in the peptide therapeutics market is driven by several factors, including technological advancements, increasing demand for targeted treatments, and the rising incidence of chronic diseases. One of the primary drivers is the expanding use of peptides in the treatment of conditions like cancer, metabolic disorders, and cardiovascular diseases, where their high specificity and low toxicity provide significant therapeutic advantages. Technological innovations in peptide stabilization and delivery are also propelling the market, making it possible to develop peptides that are more durable and effective in the body. Additionally, the rising focus on personalized medicine is increasing the demand for peptide-based treatments, as they can be tailored to target specific pathways involved in disease progression. The growing interest in immunotherapy, particularly for cancer and infectious diseases, is also contributing to market expansion, with peptide vaccines and conjugates playing a crucial role in this space. Furthermore, the relatively lower production costs associated with peptide therapeutics compared to larger biologics are encouraging pharmaceutical companies to invest more heavily in this area, further driving growth in the peptide therapeutics market.

Report Scope

The report analyzes the Peptide Therapeutics market, presented in terms of market value (USD Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments

Type (Innovative, Generic); Synthesis Technology (Liquid Phase, Solid Phase, Hybrid Phase); Application (Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory, Other Applications).

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Innovative Peptide Therapeutics segment, which is expected to reach $29.9 Billion by 2030 with a CAGR of a 2.8%. The Generic Peptide Therapeutics segment is also set to grow at 6.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $11.5 Billion in 2024, and China, forecasted to grow at an impressive 7.4% CAGR to reach $12.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in USD from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as AbbVie, Inc., Advanced Accelerator Applications SA, Akashi Therapeutics, Inc., Amgen, Inc., Anthera Pharmaceuticals, Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Peptide Therapeutics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Peptide Therapeutics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Peptide Therapeutics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Some of the 33 major companies featured in this Peptide Therapeutics market report include:

• AbbVie, Inc.
• Advanced Accelerator Applications SA
• Akashi Therapeutics, Inc.
• Amgen, Inc.
• Anthera Pharmaceuticals, Inc.
• AstraZeneca PLC
• Bachem AG
• Bristol-Myers Squibb Company
• Cardiorentis AG
• Corden Pharma International GmbH
• Debiopharm Group
• Derma Sciences, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Hanmi Pharmaceutical Co., Ltd.
• Insmed, Inc.
• Ipsen Group
• Johnson & Johnson
• Lonza Group AG
• Mallinckrodt PLC
• Merck & Co., Inc.
• MolMed S.p.A.
• Novartis AG
• Novo Nordisk A/S
• Nymox Pharmaceutical Corporation
• PAR Pharmaceutical Companies, Inc.
• PeptiDream Inc.
• Pfizer, Inc.
• PolyPeptide Group
• Radius Health, Inc.
• Repligen Corporation
• Sanofi SA
• SciClone Pharmaceuticals Holding Limited.
• Shire PLC
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• The Medicines Company
• X-GEN Pharmaceuticals, Inc.
• Zealand Pharma A/S
• Zydus Cadila